Guardant Health (GH) shares soared 6.9% in the last trading session to close at $35.28. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.3% gain over the past four weeks.The stock price surged following Guardant Health's announcement that its blood test, Shield, received FDA approval for colorectal cancer (CRC) screening in adults aged 45 and older who are at average risk for the disease. According to Guardant Health, Shield is ...